Every time a new observational data point appears, the reaction is the same: Instant celebration. Instant amplification. Zero skepticism. Doctors should be the guardrails in moments like this. Instead, many are becoming megaphones for half-baked narratives that generate attention but not accuracy. GLP-1s are already drowning in hype.Weight loss! Heart benefits! Now, anti-cancer powers? Except…
Every few weeks, a new headline seems to push GLP-1 drugs—Semaglutide and Tirzepatide—deeper into “miracle drug” territory. Weight loss. Heart benefits. Reduced inflammation. Better metabolic markers. And now… longer survival for colon cancer patients? A recently circulated data point claims that colon cancer patients using Semaglutide or Tirzepatide were less than half as likely to die within…
Pharma sees GLP-1 receptor agonists as a way to make huge profits. Once developed for Type 2 diabetes, they’ve evolved into the hottest category in weight management. The numbers are hard to ignore — real, measurable weight loss, improved metabolic profiles, and hints of cardiovascular benefit. In pharma, it’s rare when science, consumer interest, and…
There’s a seductive simplicity to it, isn’t there? Skip the messy bureaucracy, forget the government programs, and hand people cash to buy their own health insurance. Personal responsibility! Consumer choice! Market efficiency! It sounds so clean, so American, so obvious. It’s also spectacularly, dangerously wrong. I’m tired of watching this zombie idea stumble through policy debates,…
The (DTC) marketing landscape is undergoing a profound transformation. As patients become more empowered in their healthcare decisions and regulatory scrutiny intensifies, pharma marketers face a critical challenge: delivering the right message to the right patient at the right time while maintaining compliance and trust. Artificial intelligence is emerging as a game-changing solution to this…
There are moments when we must set aside our political jerseys and acknowledge a simple, uncomfortable truth: when healthcare premiums rise beyond reach for those already struggling, something fundamental has broken in our social contract. I don’t care if you’re a Democrat, Republican, Libertarian, or entirely unaffiliated. I don’t care if you believe in universal…
There’s no denying the transformative potential of GLP-1 drugs like semaglutide and tirzepatide. For many obese patients, these medications have offered something that diet and exercise alone rarely deliver—substantial and sustained weight loss. They’ve also shown promise in improving metabolic health and reducing cardiovascular risk. But as enthusiasm for GLP-1s continues to surge, we seem…
GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have become the latest medical sensation. They’re showing remarkable benefits in helping patients lose weight and manage diabetes. But somewhere along the way, the medical conversation has drifted from cautious optimism to overzealous promotion. We’re now seeing some physicians publicly suggesting that GLP-1s might be useful for everything…
The FDA occupies a unique and pivotal role: as regulator of new medicines, it must ensure therapies are safe and effective—but also that they reach patients in need without undue delay. Today, the agency is under growing scrutiny. Recent leadership upheaval and regulatory reversals—especially a sharp turn in the case of uniQure N.V.’s gene-therapy for…
The Trump administration’s announcement this week represents a significant policy shift in the fight against obesity. By expanding Medicare and Medicaid coverage for drugs like Ozempic and Wegovy (Novo Nordisk) and Mounjaro and Zepbound (Eli Lilly), millions of Americans could gain access to medications that have shown remarkable results in clinical trials—with some patients losing…